Serum Liver Fatty Acid Binding Protein Shows Good Correlation With Liver Histology in NASH

Ozenirler S., Degertekin C. K., Erkan G., Elbeg S., Tuncer C., Kandilci U., ...More

HEPATO-GASTROENTEROLOGY, vol.60, no.125, pp.1095-1100, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 60 Issue: 125
  • Publication Date: 2013
  • Doi Number: 10.5754/hge11949
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1095-1100
  • Keywords: Liver-type fatty acid binding protein, Non-alcoholic steatohepatitis, Liver histology, HEPATIC STEATOSIS, EXPRESSION, ALPHA, GAMMA
  • Gazi University Affiliated: Yes


Background/Aims: Simple, reproducible and non-invasive tests that can be used to determine the severity of non-alcoholic steatohepatitis (NASH) are needed. Liver-type fatty acid binding protein (L-FABP) plays a key role in the fatty acid metabolism of the liver. We aimed to determine whether serum L-FABP levels in patients with NASH were different from those in healthy controls, and if so, whether this was associated with the degree of fibrosis, steatosis and inflammatory activity. Methodology: Forty-seven patients with histologically confirmed NASH and 41 healthy controls were included in the study. Serum L-FABP levels were measured in all participants. Results: Mean L-FABP levels were significantly higher in patients with NASH compared to the control group (2703.19 +/- 1603.47 vs. 1684.58 +/- 860.19, p<0.001). Serum L-FABP levels showed a significant positive correlation with NAS score (p=0.03, r=0.312), the degree of fibrosis (p=0.02, r=0.324) and inflammation (p=0.03, r=0.312), BMI (p=0.05, r=0.303), serum ALT (p=0.01, r=0.28), AST (p=0.04, r=0.315), and triglyceride levels (p=0.03, r=0.328). Conclusions: Serum L-FABP levels are elevated in NASH and this elevation is positively correlated with the degree of fibrosis and inflammation. L-FABP levels may aid as a non-invasive marker in determining the severity of fibrosis and inflammation in patients with NASH.